 | Up a level |
Bahlo, J., Kutsch, N., Bergmann, M., Byrd, J., Doehner, H., Eichhorst, B., Else, M., Geisler, C., Grever, M., Lepretre, S., Neuberg, D., Oscier, D., Robak, T., Rosenquist, R., Shanafelt, T., Stilgenbauer, S. and Hallek, M. (2015). THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI)-AN INTERNATIONAL META-ANALYSIS. Haematologica, 100. S. 313 - 315. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Goede, V., Fischer, K., Engelke, A., Schlag, R., Lepretre, S., Montero, L. F. C., Montillo, M., Fegan, C., Asikanius, E., Humphrey, K., Fingerle-Rowson, G. and Hallek, M. (2015). Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia, 29 (7). S. 1602 - 1606. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Mueller, C., Cymbalista, F., Schweighofer, C., Busch, R., Porcher, R., Langerbeins, P., Cazin, B., Fink, A. -M., Dreyfus, B., Ibach, S., Lepretre, S., Fischer, K., Vehling-Kaiser, U., Eichhorst, B., Bergmann, M. A., Wendtner, C. -M., Stilgenbauer, S., Doehner, H., Leblond, V., Hallek, M. and Levy, V. (2014). Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk Binet stage A chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 37. S. 184 - 185. BASEL: KARGER. ISSN 2296-5262